Autres langues Genscript Biotech Corporation

Actions

1548

KYG3825B1059

Temps Différé Hong Kong S.E. Autres places de cotation 07:48:20 23/04/2024			Varia. 5j.	Varia. 1 janv.
11,14 ^HKD	+1,09 %		-4,30 %	-43,91 %

12/04	Genscript Biotech Corporation annonce des nominations au conseil d'administration et un changement dans la composition du comité du conseil d'administration	CI
09/04	Le médicament contre le myélome multiple réfractaire d'une unité de Genscript Biotech reçoit l'approbation de la FDA	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	17/04
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment	16/04
Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee	12/04
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	09/04
GenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability Performance	27/03
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication	19/03
Genscript Biotech Issues 444,598 Shares to Three Grantees Under Restricted Share Scheme	14/03
Genscript Biotech's 2023 Loss Widens; Misses Revenue Estimates	11/03
Genscript Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	10/03
Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board	08/03
Immunotherapy Pioneer Carl H. June, MD, Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy in Advancing Cell and Gene Therapy Breakthroughs	06/03
GenScript Biotech Corporation Expands Collaboration with Roche	05/03
GenScript Announces Its Inaugural Life Science Research Grant Project	05/02
Genscript Biotech Unit Rakes in $159 Million in Sales for Myeloma Treatment; Shares Rise 4%	24/01
Genscript Biotech Unit to Submit More Data to European, US Authorities for Approval of Myeloma Drug	24/01
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry	12/01
Genscript, Legend Biotech On-Track to Begin Production at Ghent Facilities This Year	10/01
Genscript Biotech's Subsidiary Legend Closes License Agreement with Novartis for Anti-Cancer Drug	04/01
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector	04/01
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry	04/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Genscript Biotech Corporation

Actions

1548

KYG3825B1059

Autres langues

Filtres